


PHARMACEUTICAL 2022

POINT Biopharma Global Inc. Rank 85 of 475







RealRate

PHARMACEUTICAL 2022

POINT Biopharma Global Inc. Rank 85 of 475

The relative strengths and weaknesses of POINT Biopharma Global Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of POINT Biopharma Global Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 180% points. The greatest weakness of POINT Biopharma Global Inc. is the variable Revenues, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 70%, being 346% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	243,847
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,980
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	306
Other Liabilities	66
Other Net Income	-85
Property and Equipment	19,412
Research and Development	33,505
Revenues	0
Selling, General and Administrative Expense	12,006

Output Variable	Value in 1000 USD
Assets	263,259
Liabilities	8,046
Expenses	45,817
Stockholders Equity	255,213
Net Income	-45,902
Comprehensive Net Income	-45,902
Economic Capital Ratio	70%

